The make-vs-buy decision in food manufacturing is not a unit-cost comparison — it's a strategic-control and capacity-flexibility decision that happens to have a cost number attached. Start from "what's cheaper per kilo" and you'll build a plant you can't fill, or outsource the one process your competitors can't copy. Start instead from how much control the product needs, what your cost curve actually does at low volume, and what happens to you if your co-manufacturer raises price or walks away.
This is the analysis private equity and corporate-development teams pay an expert network a four-figure hourly fee to extract. Below is the framework, the eight questions, and how investors read your decision in diligence — written the way a senior buyer would walk a colleague through it.
Key takeaways
- Unit cost is an output of the decision, not the input. Decide on strategic control and capacity risk first; cost confirms or kills the option.
- Your real cost curve is non-linear. In-house economics are dominated by utilization — a plant at 45% capacity has a wildly different unit cost than the same plant at 85%.
- Co-manufacturing trades capex for dependency. You're not buying a service; you're taking on a relationship with switching costs, exit risk, and a counterparty who knows your recipe.
- The default for a new or volatile product is "buy." You make in-house when control, IP, or scale economics earn it — not by default.
- Investors reward optionality. A decision that preserves the ability to switch, dual-source, or in-source later reads far better in diligence than a locked-in bet.
Why unit cost is the wrong place to start
Almost every make-vs-buy spreadsheet I've reviewed opens with the same line: in-house cost per unit versus co-man price per unit. Whichever is lower "wins." It's the wrong starting point for three reasons.
First, the in-house number is fiction until you fix volume. Unit cost in-house is overwhelmingly a function of utilization — fixed costs (depreciation, line crew, QA overhead, sanitation) spread across whatever you actually run. The spreadsheet usually assumes the plant runs near capacity. New products almost never do.
Second, the co-man price is a price, not a cost — it already contains their margin, their overhead absorption, and their negotiating position. Comparing your fully loaded internal cost against their quoted price is apples to oranges in your favor, and it flatters the "make" case.
Third, and most important: unit cost says nothing about the things that actually determine whether this decision ages well — control over the spec, security of supply, capacity flexibility when demand swings, and your exposure if the relationship breaks. Those are strategic variables. Cost is a constraint you apply after you've decided what the product needs.
The discipline that separates a senior buyer's analysis here is the same one behind a proper should-cost model for a food ingredient: you decompose the real cost structure rather than comparing two headline numbers.
The Make-vs-Buy Decision Ladder
Work the decision as a ladder, in order. Each rung either resolves the decision or passes it down.
- Strategic control — does owning this process protect something competitively valuable? If yes, lean make and let cost argue you out of it.
- IP / spec sensitivity — can you hand this recipe or process to a third party without losing the thing that makes it yours?
- Volume and utilization — will in-house volume realistically fill a line, or will you carry an under-utilized asset?
- Cost curve at your real volume — what's the unit cost at expected utilization, not nameplate capacity?
- Capex and payback — what's the capital outlay, and is the payback period defensible against demand uncertainty?
- Capacity flexibility — who absorbs the swing when demand is +30% or −30% from plan?
- Co-man dependency — how concentrated is the supplier base, and how much do they learn about your business?
- Exit risk — if this goes wrong, how fast and how cheaply can you reverse it?
The order matters. Most failed decisions skip rungs 1–2, jump to 3–4, and never reach 7–8 until the relationship is already in trouble.
Questions 1–2 — Strategic control and IP/spec sensitivity
Question 1: Does in-house production protect a real competitive advantage?
Be honest about what's actually differentiated. For most food products, the differentiation lives in the formulation, brand, and channel — not in the act of mixing, extruding, or filling. If a competent co-manufacturer with the right equipment can make your product to spec, the manufacturing step itself is probably not your moat, and "buy" is the rational default.
The exception is when the process is the product: a proprietary texturization, a fermentation you've spent years dialing in, a thermal or particle-size profile competitors can't replicate. There, owning the line protects the advantage, and you weight toward "make" even at a cost penalty.
Question 2: Can you outsource the spec without giving away the recipe?
This is the question people underrate. A co-manufacturer needs your formulation, your process parameters, and often your supplier list to run your product. You can protect a lot contractually, but you can't un-teach a plant how to make your hero SKU. Ask: if this co-man started a private-label line tomorrow, how exposed am I? For commodity-adjacent products, the answer is "not very." For a defensible specialty product, the answer can be "fatally" — and that pushes you toward in-house, or toward a co-man relationship structured very differently (exclusivity, tighter IP terms, deliberate fragmentation of who knows what).
Questions 3–4 — Volume, utilization, and your real cost curve
Question 3: Will your volume actually fill a line?
Industrial food lines are built for throughput. The economics assume you run them. If your realistic year-one and year-two volume fills 40–60% of a sensible minimum line, your in-house unit cost is going to be ugly, because you're absorbing the full fixed-cost base across half the output. A co-manufacturer, by contrast, blends your volume into their plant's overall utilization — that's the structural reason co-man can be cheaper for sub-scale volume even after their margin.
**Question 4: What's your cost curve at expected utilization?**
Plot unit cost against utilization, not a single point. The curve is steep at low volume and flattens as you approach capacity. The honest comparison is co-man price (flat-ish per unit, because they carry the utilization risk) versus your in-house curve at the volume you'll actually run in years 1–3 — with a sensitivity band, not a point estimate.
A useful illustrative pattern (directional, not a benchmark for your category): in-house can sit well above co-man cost below roughly half a line's capacity, cross over somewhere in the upper-middle of the utilization range, and pull meaningfully below co-man only when you're running the asset hard and consistently. Where your specific crossover sits is exactly the number a Custom Deep Dive is built to nail down.
Questions 5–6 — Capex, payback, and capacity flexibility
Question 5: What's the capex, and is the payback defensible under uncertainty?
In-house means capital — line, building or fit-out, utilities, automation, qualification. The payback math is only as good as the volume forecast underneath it, and food volume forecasts for newer products are notoriously optimistic. Stress the payback against a downside volume case, not the plan. If payback only works in the base or upside case, you're not making a manufacturing decision — you're making a bet on the forecast, and you should price the option to be wrong.
Question 6: Who carries the capacity swing?
This is the quiet superpower of co-manufacturing and the quiet liability of in-house. When demand drops, an owned plant still depreciates and still needs a crew — your downside is fixed and yours. When demand spikes, an owned plant can't flex past nameplate without overtime, weekend runs, or capex. A co-man arrangement (especially multi-sourced) lets you treat capacity as more variable: scale up by adding runs or partners, scale down by simply ordering less. If your demand is volatile or seasonal, that flexibility is worth a real premium over the lowest unit cost — and it's frequently the deciding factor a pure cost comparison misses entirely.
CTA: Run this against your specific numbers. A Custom Deep Dive (from $1,490, $300 deposit) builds a buyer-specific make-vs-buy: your real cost curve at expected utilization, the crossover volume, co-man landscape, and exit-risk read. Request a Custom Deep Dive and stop deciding capex on a single unit-cost line.
Questions 7–8 — Co-man dependency and exit risk
Question 7: How dependent do you become, and on how few?
"Buy" is not free of risk — it's a different risk. The moment you outsource, your supply security is a function of how concentrated the qualified co-man base is. If three plants on the continent can make your product and you're using one, you have leverage and a fallback. If exactly one can, you've handed them pricing power and single-point-of-failure risk. Map the qualified universe before you commit, the same way you'd run a supplier qualification process for a food ingredient. A thin universe is a strong argument for either in-house or a deliberate dual-sourcing strategy from day one.
Question 8: How fast and how cheaply can you exit?
Every "buy" decision should be made with the exit in mind. If the relationship sours, the co-man underperforms on quality, or they get acquired by a competitor — how long to qualify and transfer to an alternative? Spec documentation, owned tooling, ingredient-supply control, and a pre-qualified second source all shrink your exit cost. The decisions that wreck companies aren't the ones that go to co-man; they're the ones that go to a single co-man with no documented spec, no second source, and proprietary tooling owned by the supplier. That's not outsourcing — that's surrender with an invoice.
How investors read a make-vs-buy decision in diligence
When PE or corp-dev evaluates a target's make-vs-buy posture, they're not grading whether you picked "make" or "buy." They're reading for optionality and clear-headedness:
- Did you decide on strategy or on a spreadsheet? A decision justified purely on a unit-cost delta reads as junior. One that articulates control, capacity, and exit reads as adult.
- What's the concentration risk? Single co-man, single plant, undocumented spec, supplier-owned tooling — all red flags that get priced into the deal.
- Is the capacity bet reversible? An under-utilized owned plant is a fixed-cost millstone on the P&L. A flexible co-man network is a feature. Investors pay for the ability to flex.
- Does the cost curve hold under a downside volume case? They will rebuild your utilization assumption. If your "make" case only works at high utilization, they know it, and they'll discount it.
If you're on the buy-side screening a co-manufacturing-dependent target, the same lens runs in reverse — start by mapping the qualified co-manufacturer universe and how concentrated the target's supply actually is.
Common mistakes
- Comparing loaded internal cost to quoted external price. One has your overhead in it; the other has their margin. Normalize both to true cost-to-serve before you compare.
- Assuming nameplate utilization. The single most common error. Use your real, risk-adjusted volume.
- Treating "buy" as risk-free. Dependency, pricing power, and IP leakage are real costs — just not on the capex line.
- Ignoring the exit before signing. Document the spec, control the tooling, pre-map a second source. Decide how you get out before you get in.
- Letting cost decide a control question. If the process is genuinely your moat, a cheaper outsourced quote is not a reason to give it away.
Worked mini-example: a protein co-manufacturing decision
Take a plant-based protein brand deciding whether to build extrusion in-house or stay with a co-manufacturer. Year-one volume realistically fills perhaps 40–50% of a sensible minimum extrusion line. Walk the ladder.
Control (Q1–2): The differentiation is the formulation and the finished-texture spec, not extrusion itself — multiple qualified co-mans can run it. Control argument is moderate, not decisive. Leans buy.
Cost curve (Q3–4): At ~45% utilization, in-house unit cost sits clearly above the co-man quote. Crossover only arrives at high, sustained utilization the brand can't yet promise. Leans buy.
Capex and flexibility (Q5–6): Extrusion capex is heavy; payback only works in the upside volume case. Demand is still volatile as distribution builds — flexibility is worth a premium. Strongly leans buy.
Dependency and exit (Q7–8): The qualified co-man universe in the region is real but not deep — concentration risk is the live issue. The decision is buy — but buy with a documented spec, owned formulation, and a pre-qualified second co-man so exit cost stays low.
Net: outsource now, structure for optionality, and revisit in-house once volume reliably fills a line. That's the same logic explored in depth for pea protein co-manufacturing in North America — and it's why "buy first, earn the right to make" is the right default for most growing food products.
For the upstream version of this — which partner, once you've decided to buy — see how to choose a co-manufacturer in food.
FAQ
Is make-vs-buy mainly a cost decision? No. Cost is a constraint applied after the strategic decision. The decision is driven by how much control the product needs, your real cost curve at expected utilization, capacity flexibility, and exit risk. A choice justified purely on unit cost is the most common amateur mistake — and the easiest one for an investor to spot.
When does in-house production beat co-manufacturing economically? Typically only when you can run the asset hard and consistently — at high, sustained utilization — and when the process itself is a genuine competitive advantage worth owning. Below roughly half a line's capacity, in-house unit cost is usually higher than a co-man quote because you absorb the full fixed-cost base across too little volume.
What's the biggest risk of co-manufacturing? Dependency. A concentrated co-man base gives the supplier pricing power and creates single-point-of-failure risk. The failure mode that hurts companies is a single co-man with an undocumented spec, no second source, and supplier-owned tooling. Mitigate by documenting the spec, controlling tooling, and pre-qualifying a second source.
How do investors view make-vs-buy in diligence? They grade reasoning and optionality, not the label. They look for strategic justification, low concentration risk, reversibility, and a cost case that survives a downside volume scenario. Under-utilized owned plants are penalized; flexible, well-structured co-man networks are rewarded.
Should a new product start with make or buy? Almost always buy. New products carry volume uncertainty, and building capex against an optimistic forecast is a bet, not a manufacturing decision. Start with a co-manufacturer, preserve optionality, and earn the right to in-source once volume reliably fills a line and control or scale economics justify the capital.
Written by Amin Dabbech — 18 years in procurement across General Mills and IMERYS, specializing in food ingredients, packaging, and co-manufacturing. ProCure Navigators delivers procurement intelligence from inside the room. Request a Custom Deep Dive.
